Genentech Ends Enbrel Manufacturing Agreement; Amgen Says Supply Will Not Be Affected
This article was originally published in The Pink Sheet Daily
Genentech will pay Amgen $30 mil. to cancel Enbrel manufacturing agreement, transitioning capacity in its South San Francisco manufacturing facility to Avastin. Genentech is ramping up manufacturing at other facilities as well.
You may also be interested in...
Genentech agreed to pay Biogen $408.1 mil. for its southern California Tysabri facility to add capacity for Avastin. The facility was undergoing validation; Biogen expected to begin selling the multiple sclerosis therapy out of the facility by 2006.
Bulk drug substance for Herceptin will be manufactured at Wyeth's Andover, Mass. facility. The companies should be familiar with this type of arrangement since Genentech signed a deal in 2002 to manufacture Wyeth/Amgen's Enbrel.
A Genentech SEC filing notes that milestones such as FDA approval of the manufacturing process would not be met in the agreed upon timeline.